- Home
- TKNO vs PRTA Comparison
TKNO vs PRTA Comparison
Compare TKNO & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKNO
- PRTA
- Stock Information
- Founded
- TKNO 1996
- PRTA 2012
- Country
- TKNO United States
- PRTA Ireland
- Employees
- TKNO N/A
- PRTA N/A
- Industry
- TKNO Medicinal Chemicals and Botanical Products
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- TKNO Health Care
- PRTA Health Care
- Exchange
- TKNO Nasdaq
- PRTA Nasdaq
- Market Cap
- TKNO 356.4M
- PRTA 346.4M
- IPO Year
- TKNO 2021
- PRTA N/A
- Fundamental
- Price
- TKNO $4.49
- PRTA $6.41
- Analyst Decision
- TKNO Buy
- PRTA Buy
- Analyst Count
- TKNO 1
- PRTA 9
- Target Price
- TKNO $5.00
- PRTA $27.67
- AVG Volume (30 Days)
- TKNO 310.6K
- PRTA 1.7M
- Earning Date
- TKNO 08-12-2025
- PRTA 08-07-2025
- Dividend Yield
- TKNO N/A
- PRTA N/A
- EPS Growth
- TKNO N/A
- PRTA N/A
- EPS
- TKNO N/A
- PRTA N/A
- Revenue
- TKNO $38,250,000.00
- PRTA $137,935,000.00
- Revenue This Year
- TKNO $8.73
- PRTA N/A
- Revenue Next Year
- TKNO $16.53
- PRTA $122.02
- P/E Ratio
- TKNO N/A
- PRTA N/A
- Revenue Growth
- TKNO 3.79
- PRTA 54.55
- 52 Week Low
- TKNO $1.23
- PRTA $4.32
- 52 Week High
- TKNO $10.37
- PRTA $25.42
- Technical
- Relative Strength Index (RSI)
- TKNO 30.32
- PRTA 57.61
- Support Level
- TKNO $4.90
- PRTA $5.96
- Resistance Level
- TKNO $5.38
- PRTA $6.77
- Average True Range (ATR)
- TKNO 0.33
- PRTA 0.36
- MACD
- TKNO -0.02
- PRTA 0.14
- Stochastic Oscillator
- TKNO 3.41
- PRTA 75.80
About TKNO Alpha Teknova Inc.
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.